Skip to main content
Additional Advances in Non–Small Cell Lung Cancer Research and Clinical Trials With Ticiana Leal, MD
Additional Advances in Non–Small Cell Lung Cancer Research and Clinical Trials With Ticiana Leal, MD
Last year, Dr. Ticiana Leal, Director of the Thoracic Medical Oncology Program at Winship Cancer Institute of Emory University, recorded a continuing medical education (CME)/nursing continuing professional development (NCPD)–accredited activity title...
Read More
Additional Advances in Non–Small Cell Lung Cancer Research and Clinical Trials With Beth Sandy, MSN, CRNP
Additional Advances in Non–Small Cell Lung Cancer Research and Clinical Trials With Beth Sandy, MSN, CRNP
Just under a year ago, Beth Sandy, a Thoracic Oncology Nurse Practitioner, co-led a continuing medical education (CME)/nursing continuing professional development (NCPD)–approved activity, Harnessing Immunotherapy-Based Strategies For Advanced Non–Sm...
Read More
Additional Advances in Squamous Non–Small Cell Lung Cancer Research and Clinical Trials With Mark Kris, MD
Additional Advances in Squamous Non–Small Cell Lung Cancer Research and Clinical Trials With Mark Kris, MD
In 2022, Dr. Mark Kris, the William and Joy Ruane Chair in Thoracic Oncology at Memorial Sloan Kettering Cancer Center, served as chair of Optimizing Management of Metastatic Squamous Non–Small Cell Lung Cancer (NSCLC), a continuing medical education...
Read More
Finding Real-World Response End Points in NSCLC Data Sets With Janet Espirito, PharmD
Finding Real-World Response End Points in NSCLC Data Sets With Janet Espirito, PharmD
Oncology Data Advisor® · Finding Real-World Response End Points in NSCLC Data Sets With Janet Espirito, PharmD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Janet Espirito, PharmD, a Senior Medical D...
Read More
Additional Advances in Non–Small Cell Lung Cancer Research and Clinical Trials With Ticiana Leal, MD
Additional Advances in Non–Small Cell Lung Cancer Research and Clinical Trials With Ticiana Leal, MD
Oncology Data Advisor™ · Additional Advances in Non–Small Cell Lung Cancer Research and Clinical Trials With Ticiana Leal, MD Last year, Dr. Ticiana Leal, Director of the Thoracic Medical Oncology Program at Winship Cancer Institut...
Read More
Additional Advances in Non–Small Cell Lung Cancer Research and Clinical Trials With Beth Sandy, MSN, CRNP
Additional Advances in Non–Small Cell Lung Cancer Research and Clinical Trials With Beth Sandy, MSN, CRNP
Oncology Data Advisor™ · Additional Advances in Non–Small Cell Lung Cancer Research and Clinical Trials Just under a year ago, Beth Sandy, a Thoracic Oncology Nurse Practitioner, co-led a continuing medical education (CME)/nursing ...
Read More
Pralsetinib Approved for Non–Small Cell Lung Cancer With RET Gene Fusions
Pralsetinib Approved for Non–Small Cell Lung Cancer With RET Gene Fusions
The FDA has granted regular approval to pralsetinib (Gavreto®, Genentech, Inc.) for adult patients with metastatic rearranged during transfection (RET) fusion–positive non–small cell lung cancer (NSCLC) as detected by an FDA-approved test. Previously...
Read More
Assessing Proficiency in Squamous Non–Small Cell Lung Cancer Management
Assessing Proficiency in Squamous Non–Small Cell Lung Cancer Management
i3 Health recently provided an online continuing medical education (CME)/nursing continuing professional development (NCPD)–accredited activity that has challenged the health care team's proficiency in managing metastatic squamous non–small cell lung...
Read More
Pembrolizumab Approved for Adjuvant Treatment of Non–Small Cell Lung Cancer
Pembrolizumab Approved for Adjuvant Treatment of Non–Small Cell Lung Cancer
The FDA has approved pembrolizumab (Keytruda®, Merck) for adjuvant treatment of stage IB, II, or IIIA non–small cell lung cancer (NSCLC), following resection and platinum-based chemotherapy. "Although adjuvant chemotherapy improves overall survival i...
Read More